隶属于 circle health group ltd.
相关临床试验
21
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
15
71.4%
尚未招募
3
14.3%
招募中
2
9.5%
撤回
1
4.8%
暂无批准数据
- Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon Europe 2025 to advance its Phase 2 OCTOPOD-IV clinical trial of THEO-260 in platinum-resistant ovarian cancer. - THEO-260 is a novel oncolytic immunotherapy designed to kill both cancer cells and cancer-associated fibroblasts while inducing immune activation in stroma-rich solid tumors. - The competitive funding award validates the company's innovative approach to addressing significant unmet medical needs in patients with advanced ovarian cancer, whose life expectancy is typically one year or less. - The grant will support up to 20 patients in the Phase 2a expansion study and involves major international clinical centers including institutions in Spain, Canada, and the UK.
- Intensity Therapeutics published phase 1/2 clinical results for INT230-6 in eBioMedicine, showing a 75% disease control rate and 11.9-month median overall survival in heavily pretreated patients with advanced metastatic cancers. - Patients receiving INT230-6 at doses treating >40% of tumor burden achieved 83.3% disease control rate and 18.7-month median survival compared to 50% and 3.1 months in the <40% group. - The intratumoral therapy demonstrated abscopal effects in approximately 20% of patients and increased activated T-cell infiltration in tumor microenvironments without dose-limiting toxicities. - Based on these results across over 20 cancer types, the company has initiated a Phase 3 trial in soft tissue sarcoma and additional randomized controlled studies.
